Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pharmather Hldgs Ltd (OP:PHRRF)

0.0411 -0.0029 (-6.59%)
Streaming Delayed Price Updated: 10:57 AM EDT, Aug 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,750
Open 0.0411
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0440
Today's Range 0.0410 - 0.0411
52wk Range 0.0322 - 0.3336
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)
Marks the first milestone in PharmaTher's three-stage commercialization plan, advancing PERSONALIZ3D™ into early commercialization activitiesEstablishes the operating foundation to scale... 
Via Newsfile
News headline image
PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
Toronto, Ontario--(Newsfile Corp. - August 11, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a... 
Via Newsfile

Performance

YTD
-44.5%
-44.5%
1 Month
+12.6%
+12.6%
3 Month
-17.6%
-17.6%
6 Month
-34.0%
-34.0%
1 Year
-85.3%
-85.3%

More News

Read More
News headline image
PharmaTher Collaborates with Craft Health to Evaluate CraftMake(TM) GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides
Via Newsfile
Topics Artificial Intelligence
News headline image
PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations
Via Newsfile
Topics Artificial Intelligence
News headline image
PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval
Via Newsfile
News headline image
PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics
Via Newsfile
Topics Artificial Intelligence
News headline image
PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines
Via Newsfile
News headline image
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
Via Newsfile
News headline image
PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness
Via Newsfile
News headline image
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides
Via Newsfile
Topics Government Intellectual Property
News headline image
PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery
Via Newsfile
News headline image
PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology
Via Newsfile
Topics Intellectual Property
News headline image
PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches
Via Newsfile
Topics Intellectual Property
News headline image
PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market
Via Newsfile
News headline image
PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success
Via Newsfile
Topics Supply Chain
News headline image
PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
Via Newsfile
News headline image
PharmaTher CEO Publishes Letter to Shareholders
Via Newsfile
News headline image
PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise
Via Newsfile
News headline image
PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program
Via Newsfile
News headline image
PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale
Via Newsfile
News headline image
PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease
Via Newsfile
Topics Intellectual Property
News headline image
PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings
Via Newsfile
Topics Artificial Intelligence
News headline image
PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease
Via Newsfile
Topics Intellectual Property
News headline image
PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy
From PharmaTher Holdings Ltd.
Via GlobeNewswire
News headline image
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate over US$25 Million in Milestone and Profit-Sharing Payments
Via Newsfile

Frequently Asked Questions

Is Pharmather Hldgs Ltd publicly traded?
Yes, Pharmather Hldgs Ltd is publicly traded.
What exchange does Pharmather Hldgs Ltd trade on?
Pharmather Hldgs Ltd trades on the OTC Traded
What is the ticker symbol for Pharmather Hldgs Ltd?
The ticker symbol for Pharmather Hldgs Ltd is PHRRF on the OTC Traded
What is the current price of Pharmather Hldgs Ltd?
The current price of Pharmather Hldgs Ltd is 0.0411
When was Pharmather Hldgs Ltd last traded?
The last trade of Pharmather Hldgs Ltd was at 08/19/26 10:57 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback